Cipla to market BioQuiddity's products in EU

Cipla Europe NV (Cipla), a wholly-owned subsidiary of Cipla Limited and the US-based BioQuiddity Inc. have entered into a marketing alliance for the European Union markets. Under the agreement, Cipla will sell BioQuiddity's anaesthetic products in certain European markets.

Cipla will launch the 'OneDose ReadyfusOR' pre-filled with Ropivacaine under its own label into the German market late this year.

Joshua Kriesel, president and CEO, BioQuiddity said, "Cipla's strong commercial record puts them in an outstanding position to detail the OneDose ReadyfusOR's safety, sterility, and ease of use value proposition objectives."